Ezetimibe Plus Rosuvastatin for Hypertriglyceridemia and Cardiac Event Reduction

Primary Mechanism and Lipid Effects

The combination of ezetimibe and rosuvastatin achieves >50% LDL-C reduction from baseline, substantially exceeding rosuvastatin monotherapy, in high-risk patients 1, 2
The European Society of Cardiology recommends the combination of ezetimibe and rosuvastatin for high-risk patients to achieve LDL-C <30 mg/dL 1, 2

Adding ezetimibe to statin therapy reduces the composite endpoint of cardiovascular death, myocardial infarction, stroke, hospital admission, and coronary revascularization in high-risk patients 1, 2
High-risk patients derive the greatest absolute benefit from combination therapy, with a significant reduction in cardiovascular events 1, 2
Patients achieving LDL-C <30 mg/dL had the lowest cardiovascular event rates over 6 years with comparable safety profiles 1, 2

The combination of rosuvastatin and ezetimibe allows 94% of patients to reach ATP III LDL-C goals (<100 mg/dL), compared to 79% with rosuvastatin alone 3
For very high-risk patients requiring LDL-C <70 mg/dL, 79.6% achieve goal with combination therapy versus only 35% with rosuvastatin monotherapy 3

The European Society of Cardiology consensus panel recommends using combination therapy as the default strategy rather than stepwise titration for high-risk patients 1, 2
For patients not at LDL-C goal on rosuvastatin 5-10 mg, adding ezetimibe 10 mg is recommended rather than uptitrating rosuvastatin dose 3

The combination of ezetimibe and rosuvastatin is as safe as statin monotherapy, with no increased incidence of treatment-related or serious adverse events 1, 2
The combination allows avoidance of high-intensity statin doses that may cause myopathy while achieving superior LDL-C reduction 2

Fixed-dose combinations of ezetimibe and rosuvastatin offer improved adherence through simplified regimens 1, 2
The combination provides synergistic effects that exceed the sum of individual drugs 3

Ezetimibe 10 mg should be refilled monthly (30 tablets) to maintain optimal daily dosing, as supported by European Heart Journal data. 4

The International Lipid Expert Panel (2024) recommends high‑intensity statin therapy (rosuvastatin 20‑40 mg or atorvastatin 40‑80 mg) combined with ezetimibe before adding a PCSK9 inhibitor. 5
For patients with established ASCVD not at LDL‑C goal on statin‑ezetimibe, a triple regimen of rosuvastatin 5 mg, ezetimibe 10 mg, and evolocumab 140 mg is considered appropriate, though rosuvastatin 5 mg is low‑intensity and may be suboptimal. 5

LDL‑C target for high‑risk ASCVD is < 55 mg/dL (< 1.4 mmol/L); recent LDL‑C should be verified to assess whether the current regimen meets this goal. 5
If LDL‑C is above target, rosuvastatin should be intensified to 20 mg daily (or up to 40 mg if tolerated) before relying solely on evolocumab. 5
Lipid panels should be repeated 4‑6 weeks after any dose adjustment to determine if LDL‑C goals are achieved. 5

Adding a PCSK9 inhibitor without first maximizing statin (≥ 20 mg rosuvastatin) plus ezetimibe therapy is discouraged. 5
To avoid non‑adherence, clinicians should explore reimbursement programs or patient‑assistance options for PCSK9 inhibitors. 5